Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

This summary presents current health and legal developments including wildfire smoke health risks, Kroger's opioid settlement ...

The president-elect might bring back efforts to make other countries pay more for drugs, but there are pitfalls.

There is a photo that exemplifies the paradox of Robert F. Kennedy Jr.’s nomination as secretary of the Health and Human ...

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Medicare’s block on obesity medication coverage ... loss therapies like Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound (tirzepatide), which generally have to be paid for ...

Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

More than two years after the passage of the Inflation Reduction Act (“IRA”) and the Centers for Medicare and Medicaid Services’ (“CMS’”) ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.